WallStSmart

Abbott Laboratories (ABT)vsSpotify Technology SA (SPOT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 158% more annual revenue ($44.33B vs $17.19B). ABT leads profitability with a 14.7% profit margin vs 12.9%. ABT appears more attractively valued with a PEG of 1.52. SPOT earns a higher WallStSmart Score of 62/100 (C+).

ABT

Buy

51

out of 100

Grade: C-

Growth: 5.3Profit: 6.5Value: 7.3Quality: 4.8
Piotroski: 3/9

SPOT

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 8.7Quality: 7.5
Piotroski: 4/9Altman Z: 2.66
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-315.5%)

Margin of Safety

-315.5%

Fair Value

$25.23

Current Price

$104.83

$79.60 premium

UndervaluedFair: $25.23Overvalued
SPOTUndervalued (+13.1%)

Margin of Safety

+13.1%

Fair Value

$560.66

Current Price

$473.21

$87.45 discount

UndervaluedFair: $560.66Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT3 strengths · Avg: 8.3/10
Market CapQuality
$180.82B9/10

Large-cap with strong market position

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$2.63B8/10

Generating 2.6B in free cash flow

SPOT3 strengths · Avg: 9.3/10
Return on EquityProfitability
31.9%10/10

Every $100 of equity generates 32 in profit

Market CapQuality
$99.82B9/10

Large-cap with strong market position

Debt/EquityHealth
0.289/10

Conservative balance sheet, low leverage

Areas to Watch

ABT4 concerns · Avg: 3.8/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

P/E RatioValuation
28.1x4/10

Moderate valuation

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SPOT4 concerns · Avg: 3.5/10
PEG RatioValuation
1.994/10

Expensive relative to growth rate

Price/BookValuation
10.1x4/10

Trading at 10.1x book value

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

P/E RatioValuation
40.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : SPOT

The strongest argument for SPOT centers on Return on Equity, Market Cap, Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : SPOT

The primary concerns for SPOT are PEG Ratio, Price/Book, EPS Growth. A P/E of 40.5x leaves little room for execution misses.

Key Dynamics to Monitor

SPOT carries more volatility with a beta of 1.72 — expect wider price swings.

SPOT is growing revenue faster at 6.8% — sustainability is the question.

ABT generates stronger free cash flow (2.6B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SPOT scores higher overall (62/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Spotify Technology SA

COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA

Spotify Technology SA, provides audio streaming services worldwide. The company is headquartered in Luxembourg, Luxembourg.

Want to dig deeper into these stocks?